Investor and Entrepreneur · Co-Founder
Terray Therapeutics
Terray Therapeutics utilizes a closed-loop design-make-test-analyze workflow, integrating high-resolution quantitative data from over two billion target-ligand binding measurements to enhance small molecule drug discovery. The platform accelerates the identification of potent small molecules for various therapeutic targets, addressing the inefficiencies and high costs associated with traditional drug development processes.
- Artificial Intelligence
- Biotechnology
- Hardware
Updated 5 months ago
Funding
Raised to date
$120MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional small molecule drug discovery is slow, expensive, and inefficient, often struggling to identify potent molecules for therapeutic targets. The process lacks the ability to generate high-quality data at scale, which is crucial for accurate molecular property prediction and effective exploration of chemical space.
Solution
Terray Therapeutics offers a platform that integrates high-resolution quantitative data from over two billion target-ligand binding measurements to enhance small molecule drug discovery. Their closed-loop design-make-test-analyze workflow accelerates the identification of potent small molecules for various therapeutic targets. The platform emphasizes both wet lab science and AI, enabling the company to tackle complex therapeutic challenges by rapidly identifying and evaluating multiple points of intervention in a pathway to treat disease. This approach improves the speed, cost, and success rate of small molecule drug discovery and development.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies seeking to accelerate and improve the efficiency of their small molecule drug discovery programs.
Features
- Experimental dataset includes more than two billion unique target-ligand binding measurements, growing by 300 million new measurements every month.
- High-resolution quantitative data supported by an average of 25 independent data points per measurement.
- Closed-loop iteration cycle (design-make-test-analyze) takes less than a month per target.
- AI-driven platform enables rapid identification of potent, selective small molecules for many targets in parallel.
- Focus on immunology within the internal pipeline.
- Partnerships with large pharma and biotech companies to apply the platform to a wide range of challenging targets and therapeutic areas.